EVLP

AcronymDefinition
EVLPEx-Vivo Lung Perfusion
EVLPEducation Volume License Program
References in periodicals archive ?
The Vancouver lung transplant clinic made approximately 50 lung transplants in 2018, and will be the first in Canada to use the XPS with STEEN solution during the EVLP.
Since then, Lung Bioengineering has used the XPS technology to offer centralized EVLP to transplant centres on a fee-for-service basis, in order to increase the supply of transplantable lungs to address needless patient deaths on the transplant waitlist.
The company's llead eVLP asset is a preventative cytomegalovirus vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials.
The company said with its integrated Hamilton C2 ventilator and MAQUET CardioHelp centrifugal pump, XPS is the most flexible and complete platform for EVLP on the market and gives the transplantation team full control of the entire process.
Lung conditioning using EVLP is able to improve the function of lungs initially rejected for transplant [205].
Prof Fisher said: "If we can show that survival in the first 12 months after transplant with EVLP improved lungs is comparable to that achieved with standard donor lungs then we will know this is a successful and effective technique for the NHS."
"However, we will also carefully check in the study that there are no more early complications, such as a longer stay on intensive care or more frequent infections or episodes of transplant rejection in the EVLP improved lungs compared to standard donor lungs."
This approval implies that STEEN solution, XPS and the accompanying single-use articles are the only medical device products that are approved for Ex Vivo Lung Perfusion (EVLP) of initially unacceptable donated lungs at body temperature.
XVIVO Perfusion Inc, a subsidiary of medical technology company XVIVO Perfusion AB (STO: XVIVO) and biotechnology company United Therapeutics Corporation (Nasdaq: UTHR) announced on Tuesday that the use of XVIVO's ex-vivo lung perfusion (EVLP) technology will be incorporated into the Silver Spring,Maryland laboratory of Lung Bioengineering Inc, a subsidiary of United Therapeutics' public benefit corporation subsidiary Lung Biotechnology PBC.
United Therapeutics and XVIVO Perfusion, a subsidiary of XVIVO Perfusion AB, announced that the use of XVIVO's ex-vivo lung perfusion, or EVLP, technology will be incorporated into the Silver Spring, Maryland laboratory of Lung Bioengineering Inc., a subsidiary of United Therapeutics' public benefit corporation subsidiary Lung Biotechnology PBC.
Ex vivo lung perfusion (EVLP) has emerged as an essential tool for the reassessment, under a controlled scenario, of lungs from heart-beating donors (HBDs) that initially did not meet transplantation criteria [3-8].